AEGIRBIO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.519 SEK | +4.74% |
|
+3.59% | -55.64% |
| 04-19 | AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract | MT |
| 04-09 | AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas | MT |
| Sales 2021 | 13.28 145.3 1.06K | Sales 2022 | 1.71 18.66 136.6 | Capitalization | 42.8M 468M 3.43B |
|---|---|---|---|---|---|
| Net income 2021 | -92M -1.01B -7.37B | Net income 2022 | -363M -3.97B -29.07B | EV / Sales 2021 | 72,019,947 x |
| Net cash position 2021 | 32.63M 357M 2.61B | Net cash position 2022 | 7.44M 81.34M 595M | EV / Sales 2022 | 20,730,843 x |
| P/E ratio 2021 |
-9.29
x | P/E ratio 2022 |
-0.11
x | Employees | 13 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.58% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.74% | ||
| 1 week | +3.59% | ||
| Current month | -29.24% | ||
| 1 month | -28.36% | ||
| 3 months | -44.79% | ||
| 6 months | -40.99% | ||
| Current year | -55.64% |
1 week
0.49
0.64
1 month
0.491.00
Current year
0.491.17
1 year
0.492.10
3 years
0.49399.50
5 years
0.49399.50
10 years
0.49399.50
| Managers | Title | Age | Since |
|---|---|---|---|
Marco Witteveen
CEO | Chief Executive Officer | - | 14/06/23 |
| Director of Finance/CFO | - | 18/04/23 | |
Vasiliki Fragkou
COO | Chief Operating Officer | - | 10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 31/01/20 | |
| Chairman | 67 | 30/11/19 | |
Sofia Bertling
BRD | Director/Board Member | 54 | 31/05/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.519 | +4.74% | 38,405 |
| 25/04/24 | 0.4955 | +0.92% | 95,441 |
| 24/04/24 | 0.491 | -1.80% | 323,437 |
| 23/04/24 | 0.5 | -5.30% | 205,924 |
| 22/04/24 | 0.528 | +5.39% | 287,230 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:13 pm
More quotes
AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.
Calendar
16/05/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -55.64% | 1.46M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- AEGIR Stock
